TAKEDA PHARMACEUTICAL CO LTD ADR

NYSE: TAK (Takeda Pharmaceutical Company L)

Kemas kini terakhir: 28 Nov, 5:34AM

14.52

0.02 (0.14%)

  • 1H 0.14%
  • 5H 1.54%
  • 1B 6.84%
  • 6B -3.14%
  • Tahun Ke Tarikh 9.58%
  • 1T 5.22%
  • 5T -22.64%
Penutupan Terdahulu 14.50
Buka 14.51
Jumlah Dagangan 2,121,905
Purata Dagangan (3B) 2,975,236
Modal Pasaran 48,318,943,232
Harga / Pendapatan (P/E TTM) 207.43
Harga / Pendapatan (P/E Ke hadapan) 9.58
Harga / Jualan (P/S) 1.64
Harga / Buku (P/B) 1.00
Julat 52 Minggu
12.80 (-11%) — 15.69 (8%)
Tarikh Pendapatan 29 Jan 2026
Hasil Dividen (DY TTM) 4.61%
Margin Keuntungan 2.36%
Margin Operasi (TTM) 11.68%
EPS Cair (TTM) 0.230
Pertumbuhan Hasil Suku Tahunan (YOY) 0.20%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -77.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 73.36%
Nisbah Semasa (MRQ) 1.01
Aliran Tunai Operasi (OCF TTM) 1.06 T
Aliran Tunai Bebas Leveraj (LFCF TTM) 735.62 B
Pulangan Atas Aset (ROA TTM) 2.40%
Pulangan Atas Ekuiti (ROE TTM) 1.52%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Menaik Bercampur
Drug Manufacturers - Specialty & Generic (Global) Menaik Bercampur
Stok Takeda Pharmaceutical Company L Bercampur Bercampur

AISkor Stockmoo

1.4
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam NA
Volatiliti Harga -1.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal 2.0
Purata 1.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
TAK 48 B 4.61% 207.43 1.00
ZTS 53 B 0.83% 20.21 10.46
HLN 44 B 1.20% 22.18 2.06
RDY 12 B 54.73% 17.71 2.89
TEVA 31 B - 44.08 4.23
BHC 2 B - 23.46 -

Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Large Core
% Dimiliki oleh Orang Dalam 0.01%
% Dimiliki oleh Institusi 2.30%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
07 Nov 2025 Pengumuman Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
03 Nov 2025 Pengumuman New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
30 Oct 2025 Pengumuman Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
27 Oct 2025 Pengumuman HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
21 Oct 2025 Pengumuman Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
21 Oct 2025 Pengumuman HEALWELL's DARWEN(TM) AI Platform Demonstrates One of the World's First Examples of Using AI to Generate Regulatory-Grade Real-World Data (RWD) for Supporting Patient Access and Advancing the Pharmaceutical Industry
23 Sep 2025 Pengumuman 20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
16 Sep 2025 Pengumuman Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
11 Sep 2025 Pengumuman Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
08 Sep 2025 Pengumuman Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
05 Sep 2025 Pengumuman U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
Papar semua
Hasil Dividen (DY TTM) 4.61%
Purata Hasil Dividen 5T 3.39%
Nisbah Pembayaran 289.45%
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
30 Mar 2023 15 Mar 2023 10 Jul 2023 0.30996 Tunai
29 Sep 2022 13 Sep 2022 12 Dec 2022 0.329553 Tunai
30 Mar 2022 04 Mar 2022 11 Jul 2022 0.330062 Tunai
29 Sep 2021 - 13 Dec 2021 0.396898 Tunai
30 Mar 2021 15 Mar 2021 12 Jul 2021 0.406627 Tunai
29 Sep 2020 - 11 Dec 2020 0.430533 Tunai
30 Mar 2020 - 06 Jul 2020 0.419053 Tunai
27 Sep 2019 09 Sep 2019 12 Dec 2019 0.411118 Tunai
28 Mar 2019 16 Mar 2019 10 Jul 2019 0.417168 Tunai
26 Sep 2018 - 13 Dec 2018 0.395501 Tunai
27 Mar 2018 - 09 Jul 2018 0.40643 Tunai
27 Sep 2017 - 11 Dec 2017 0.39946 Tunai
29 Mar 2017 - 10 Jul 2017 0.39892 Tunai
28 Sep 2016 - 12 Dec 2016 0.392415 Tunai
29 Mar 2016 - 11 Jul 2016 0.43705 Tunai
28 Sep 2015 - 11 Dec 2015 0.365323 Tunai
27 Mar 2015 - 09 Jul 2015 0.365289 Tunai
25 Sep 2014 - 11 Dec 2014 0.378342 Tunai
26 Mar 2014 - 10 Jul 2014 0.443655 Tunai
25 Sep 2013 - 12 Dec 2013 0.436978 Tunai
26 Mar 2013 - 08 Jul 2013 0.457131 Tunai
25 Sep 2012 - 13 Dec 2012 0.545983 Tunai
27 Mar 2012 - 09 Jul 2012 0.563768 Tunai
27 Sep 2011 - 12 Dec 2011 0.578629 Tunai
28 Mar 2011 - 07 Jul 2011 0.555761 Tunai
27 Sep 2010 - 13 Dec 2010 0.533229 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2023 0.310 1 2.17
2022 0.660 2 4.23
2021 0.804 2 5.90
2020 0.850 2 4.67
2019 0.828 2 4.20
2018 0.802 2 4.77
2017 0.798 2 2.81
2016 0.829 2 3.99
2015 0.731 2 2.92
2014 0.822 2 3.96
2013 0.894 2 3.88
2012 1.11 2 5.00
2011 1.13 2 5.15
2010 0.533 1 2.19
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda